Subscribe: MedWorm: Corticosteroid Therapy
http://www.medworm.com/rss/medicalfeeds/therapies/Corticosteroid-Therapy.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
asthma  copd  corticosteroid  corticosteroids  drug  inhaled corticosteroids  inhaled  medworm  news  patients  source  study  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: MedWorm: Corticosteroid Therapy

MedWorm: Corticosteroid Therapy News



MedWorm.com provides a medical RSS filtering service. Thousands of medical RSS feeds are combined and output via different filters. This feed contains the latest news in Corticosteroid Therapy



Last Build Date: Fri, 16 Feb 2018 23:37:28 +0100

 



Discovery the phenomenon of polymorphism in the atomic structure of the methylprednisolone aceponate

Thu, 15 Feb 2018 05:00:00 +0100

(Lobachevsky University) UNN researchers have discovered the phenomenon of polymorphism in the atomic structure of the methylprednisolone aceponate crystal. They managed to synthesize a single crystal of corticosteroid hormone methylprednisolone aceponate, which was of a sufficient size for X-ray diffraction studies. (Source: EurekAlert! - Medicine and Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




GSK seeks expanded label for Trelegy Ellipta inhaler in EU

Wed, 14 Feb 2018 15:08:05 +0100

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) have submitted data to the European Medicines Agency in the hopes of expanding the label for its once-daily, triple combination inhaler, Trelegy Ellipta. The drug-device combo was approved in Europe in November last year as a maintenance treatment for adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a inhaled corticosteroid combined with a long-acting beta-adrenergic agonist. GSK and Innoviva hope that data from its Impact trial will support the product’s use in a broader population of COPD patients who are at risk of exacerbation. Get the full story at our sister site, Drug Delivery Business News. The post GSK seeks expanded label for Trelegy Ellipta inhaler in EU a...



Widely Used COPD Meds Tied to Increased Fracture Risk

Tue, 13 Feb 2018 12:02:25 +0100

TUESDAY, Feb. 13, 2018 -- Many patients with chronic obstructive pulmonary disease (COPD) are placed on powerful inhaled corticosteroid therapy to ease symptoms. But new research suggests the treatment might raise their odds for bone... (Source: Drugs.com - Daily MedNews)



Teva launches breath-activated asthma aerosol in U.S.

Mon, 12 Feb 2018 15:08:33 +0100

Teva Pharmaceuticals (NYSE:TEVA) has launched its Qvar RediHaler inhalation aerosol in the U.S., marking the first time a breath-actuated inhaled corticosteroid is available for asthma patients as a prophylactic therapy. In contrast to traditional metered-dose inhalers, Teva’s Qvar RediHaler sends medication into the user’s lungs as they inhale. This feature eliminates the need for hand-breath coordination, according to Teva. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches breath-activated asthma aerosol in U.S. appeared first on MassDevice. (Source: Mass Device)



Probiotics May Improve Pediatric AD Symptoms

Sun, 11 Feb 2018 18:35:02 +0100

(MedPage Today) -- Probiotics may also reduce need for topical corticosteroids (Source: MedPage Today Pediatrics)



Study: Long-term use of inhaled corticosteroids may heighten risk of bone fractures in COPD patients

Tue, 06 Feb 2018 20:03:19 +0100

Researchers reported this month that in men and women with chronic obstructive pulmonary disease, long-term use of inhaled corticosteroids may be linked to an increased risk of bone fractures. Previous research has shown that the inhaled drugs, used to treat COPD, impact bone mineral density based on the dose of the corticosteroid, especially in post-menopausal women. Get the full story at our sister site, Drug Delivery Business News. The post Study: Long-term use of inhaled corticosteroids may heighten risk of bone fractures in COPD patients appeared first on MassDevice. (Source: Mass Device)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Long-term usage of inhaled corticosteroids may increase risk of bone fractures in patients with COPD

Mon, 05 Feb 2018 05:00:00 +0100

(American College of Chest Physicians) A study published in the February journal CHEST ® suggests long-term inhaled corticosteroids (ICS) in patients with COPD may increase risk of bone fractures in both men and women. Previous studies have suggested that ICS negatively impacts bone mineral density in a dose-dependent fashion, particularly affecting postmenopausal women, but it has been unclear whether these effects translate to bone fractures. (Source: EurekAlert! - Medicine and Health)



Do Corticosteroids Improve Diabetic Macular Edema Outcomes? Do Corticosteroids Improve Diabetic Macular Edema Outcomes?

Tue, 30 Jan 2018 14:21:00 +0100

Drs Matt Starr and Sophie Bakri on a randomized trial studying the value of adding intravitreal dexamethasone to anti-VEGF therapy.Medscape Ophthalmology (Source: Medscape Today Headlines)



Blood Eosinophil Counts Predict COPD Exacerbations, Response to Steroids Blood Eosinophil Counts Predict COPD Exacerbations, Response to Steroids

Mon, 29 Jan 2018 21:51:05 +0100

Higher blood eosinophil counts are associated with an increased risk of exacerbation and a better chance of responding to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD), according to a post hoc analysis.Reuters Health Information (Source: Medscape Today Headlines)



COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma

Fri, 26 Jan 2018 20:36:56 +0100

A new study provides preliminary evidence that tiotropium, a long-acting anticholinergic drug used for chronic obstructive pulmonary disease (COPD), is safe and effective in preschool-age children with asthma symptoms not well controlled by inhaled corticosteroids.Reuters Health Information (Source: Medscape Medical News Headlines)



EMA committee backs label change for GSK ’s Relvar Ellipta asthma therapy

Fri, 26 Jan 2018 14:44:03 +0100

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency committee has backed an updated label for its once-daily asthma therapy, Relvar Ellipta. If granted marketing authorization by the European Commission, the combination drug treatment will be approved for use in patients whose asthma is already controlled on an inhaled corticosteroid and a long-acting beta-2-agonist. Get the full story at our sister site, Drug Delivery Business News. The post EMA committee backs label change for GSK’s Relvar Ellipta asthma therapy appeared first on MassDevice. (Source: Mass Device)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Diagnosing and Managing CIRCI in Critically Ill Patients II Diagnosing and Managing CIRCI in Critically Ill Patients II

Fri, 05 Jan 2018 06:14:36 +0100

This article provides updated recommendations for the management of acute illnesses that may be complicated by critical illness-related corticosteroid insufficiency.Critical Care Medicine (Source: Medscape Today Headlines)



A Guide To Managing RVO: Ophthalmology Times

Tue, 02 Jan 2018 21:30:00 +0100

(MedPage Today) -- Also, adding corticosteroid implant may not improve visual acuity (Source: MedPage Today Primary Care)



Si-Bone touts BCBS SI joint fusion operation assessment rating upgrade

Tue, 02 Jan 2018 15:49:12 +0100

Si-Bone today touted that the Blue Cross Blue Shield Association assigned triangular implants for SI joint fusion, including the company’s iFuse implant, as a “moderate” quality evidence recommendation after an extensive review of safety and effectiveness data on the devices and procedures. The “moderate” grade is the second highest on BCBSA’s four-tier rating system, according to San Jose, Calif.-based Si-Bone, and requires sufficient clinical evidence to judge health outcomes with the devices. In the update, the BCBSA states that evidence is sufficient to show that the device, used in individuals with common disorders affecting the sacroiliac joint, produces meaningful improvement in the net health outcome of patients, Si-Bone said. The company said t...



Diagnosing and Managing CIRCI in Critically Ill Patients Diagnosing and Managing CIRCI in Critically Ill Patients

Fri, 29 Dec 2017 05:14:42 +0100

This article provides updated recommendations for the diagnosis and management of critical illness-related corticosteroid insufficiency.Critical Care Medicine (Source: Medscape Today Headlines)



Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)

Fri, 22 Dec 2017 10:53:53 +0100

This review found very low-quality evidence which neither supported nor refuted corticosteroid use in this setting. Further high quality studies are needed to determine if corticosteroids are efficacious in this setting. (Source: Current Awareness Service for Health (CASH))

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




FDA Axes Boxed Warning from Inhaled Corticosteroids Plus Long-Acting Beta Agonists

Fri, 22 Dec 2017 03:20:37 +0100

The FDA is removing the boxed warning from drugs containing both an inhaled corticosteroid and a long-acting beta agonist after studies found that... (Source: Physician's First Watch current issue)



Obesity Tied to Greater Asthma Impairment in Preschoolers

Thu, 21 Dec 2017 18:00:00 +0100

But responsiveness to inhaled corticosteroids is not reduced for overweight/obese preschoolers (Source: Pulmonary Medicine News - Doctors Lounge)



AstraZeneca wins FDA nod to remove boxed warning from asthma drug label

Thu, 21 Dec 2017 17:14:53 +0100

After reviewing results from trials involving more than 41,000 asthma patients, the FDA has agreed to remove the boxed warning of serious asthma-related outcomes for AstraZeneca‘s (NYSE:AZN) Symbicort product. Patients using Symbicort, which combines an inhaled corticosteroid and a long-acting beta2-adrenergic agonist in a single inhaler, did not experience a significant increase in the risk of a serious asthma-related event, according to data from four clinical trials. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca wins FDA nod to remove boxed warning from asthma drug label appeared first on MassDevice. (Source: Mass Device)



FDA Drops Boxed Warning on LABA/ICS Asthma/COPD Meds FDA Drops Boxed Warning on LABA/ICS Asthma/COPD Meds

Thu, 21 Dec 2017 16:31:07 +0100

FDA-required postmarket safety studies find no increased risk for serious asthma-related outcomes with products containing a long-acting beta-agonist and inhaled corticosteroid.News Alerts (Source: Medscape Medical News Headlines)



FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)

Wed, 20 Dec 2017 22:40:00 +0100

A U.S. Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. In 2011, we required the drug companies that market LABAs to conduct these trials to evaluate the safety of LABAs when used in combination with ICS, and we reviewed the results of these recently completed trials. Based on our review, the Boxed Warning, our most prominent warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. (Source: FDA Center for Drug Evaluation and Research - What's New)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs)

Wed, 20 Dec 2017 22:36:00 +0100

[04-15-2011] To further evaluate the safety of Long-Acting Beta-Agonists (LABAs) when used in combination with inhaled corticosteroids for the treatment of asthma, the U.S. Food and Drug Administration (FDA) is requiring the manufacturers of LABAs to conduct five randomized, double-blind, controlled clinical trials comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone. (Source: FDA Center for Drug Evaluation and Research - What's New)



Does red cell distribution width predict outcome in traumatic brain injury: comparison to corticosteroid randomization after significant head injury - Sadaka F, Doctors N, Pearson T, Snyders B, O'Brien J.

Wed, 20 Dec 2017 14:20:29 +0100

BACKGROUND: Traumatic brain injury (TBI) is a leading cause of death and disability. The role of red cell distribution width (RDW) as a prognostic biomarker for outcome in TBI patients is unknown. Based on the corticosteroid randomization after significant... (Source: SafetyLit)



Intra-Articular Corticosteroid Injections in Knee OA Intra-Articular Corticosteroid Injections in Knee OA

Fri, 24 Nov 2017 05:14:38 +0100

Intra-articular corticosteroid injections are a non-surgical treatment option for knee OA, but certain patient factors may impact efficacy.Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape Today Headlines)



After FDA nod, Flexion launches osteoarthritis injection

Mon, 20 Nov 2017 14:11:43 +0100

Flexion Therapeutics (NSDQ:FLXN) today launched its Zilretta therapy designed to help patients manage pain associated with osteoarthritis of the knee. The Burlington, Mass.-based company’s extended-release intra-articular injection combines a commonly administered, short-acting corticosteroid with a polylactic-co-glycolic acid matrix using Flexion’s microsphere technology. Get the full story at our sister site, Drug Delivery Business News. The post After FDA nod, Flexion launches osteoarthritis injection appeared first on MassDevice. (Source: Mass Device)



Corticosteroids do not increase risk of bone fractures

Thu, 16 Nov 2017 12:00:00 +0100

According to a study, published inJAMA Pediatrics, children on daily inhalable corticosteroids do not have an increased risk of bone fractures.Medscape (Source: Society for Endocrinology)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Inhaled Corticosteroids Not Linked to Fracture in Children

Tue, 14 Nov 2017 18:00:00 +0100

Systemic, but not inhaled, corticosteroids associated with higher fracture risk in pediatric asthma patients (Source: Pulmonary Medicine News - Doctors Lounge)



Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate ® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura

Fri, 10 Nov 2017 12:30:28 +0100

Positive Opinion Based on Five Studies Demonstrating Nplate Reduces Rates of Bleeding in Children With Rare Blood Disorder THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate® (romiplostim) to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) for patients one year of age and older who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). The positive CHMP opinion was based on five studies evaluating the safety and ef... (Source: Amgen News Release)



Allergy Experts: Single Drug Best for Allergic Rhinitis

Thu, 09 Nov 2017 17:00:00 +0100

(MedPage Today) -- AAAAI, ACAAI advise against intranasal corticosteroid with oral antihistamine (Source: MedPage Today Allergy)



Topical corticosteroids reduce retinoid irritation, study shows

Wed, 01 Nov 2017 04:00:00 +0100

Transient topical corticosteroids could take edge off severe irritation from topical retinoid acne treatment without decreasing efficacy. (Source: Dermatology Times)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Corticosteroids for Treatment of Sore Throat Corticosteroids for Treatment of Sore Throat

Fri, 13 Oct 2017 04:14:35 +0100

Do the benefits outweigh the potential risks of using corticosteroids as an adjunct treatment for acute sore throat?The BMJ (formerly known as the British Medical Journal) (Source: Medscape Today Headlines)



Boehringer Ingelheim, Anthem partner for largest real-world COPD trial

Thu, 12 Oct 2017 16:36:37 +0100

As part of a research collaboration launched in 2014, Boehringer Ingelheim and Anthem have partnered to study people with chronic obstructive pulmonary disease in real-world settings to assess how commonly-prescribed drugs may reduce the occurrence of COPD exacerbations. The team, which also includes Anthem’s outcomes research subsidiary HealthCore, plans to investigate whether adding an inhaled corticosteroid to a LAMA-LABA combination provides a meaningful benefit – a question under debate in the respiratory space. Get the full story at our sister site, Drug Delivery Business News. The post Boehringer Ingelheim, Anthem partner for largest real-world COPD trial appeared first on MassDevice. (Source: Mass Device)



Corticosteroids vs. NSAIDs

Thu, 12 Oct 2017 07:00:00 +0100

Title: Corticosteroids vs. NSAIDsCategory: MedicationsCreated: 10/12/2017 12:00:00 AMLast Editorial Review: 10/12/2017 12:00:00 AM (Source: MedicineNet Medications General)



First UK guideline published for lupus management in adults

Mon, 09 Oct 2017 15:02:00 +0100

The smallest effective dose of corticosteroids should be used to treat adult patients with lupus, according to the first ever UK guideline specifically for the management of the condition. (Source: Nursing Times)



How Common Is Hereditary Angioedema?

Mon, 09 Oct 2017 00:58:55 +0100

Discussion Angioedema is edema that is non-pitting, self-limited occurring in non-dependent areas usually in an asymmetric distribution usually on the lips, face, hands, feet, genitals and also in the bowel. It usually develops over minutes to hours (often 1-2 hours) with resolution usually within 24-48 hours. Angioedema often occurs with urticaria but 20% of patients may have isolated angioedema. Acute allergic angioedema is often caused by drugs (including antibiotics and non-steroidal anti-inflammatory drugs), foods, infections, insects, various organic substances (i.e. latex, preservatives, formaldehyde, etc.), and other allergens such as animal danders, dust mites, pollens and molds. Common triggers in children are infections including the viruses Coxsackie A, Epstein-Barr virus, Hepa...

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




FDA OKs First Extended-Release Corticosteroid Shot for Knee OA FDA OKs First Extended-Release Corticosteroid Shot for Knee OA

Fri, 06 Oct 2017 22:02:56 +0100

Triamcinolone acetonide extended-release injectable suspension (Zilretta) is a nonopioid option that provides knee OA pain relief over 12 weeks.FDA Approvals (Source: Medscape Med Students Headlines)



Vitamin D may prevent asthma worsening for some

Thu, 05 Oct 2017 18:00:00 +0100

Conclusion This review gathers the available trial evidence to address the specific question of whether giving people with asthma vitamin D supplements could have an effect on how many asthma exacerbations they have. The review has many strengths. It only included double-blind trials, where participants and assessors didn't know if people were taking vitamin D or a placebo. Researchers also made careful attempts to gather all relevant data and information on confounding factors, and all but one trial had a low risk of bias. But there are some limitations to bear in mind: With the relatively small number of trials and participants, the outcome of interest – exacerbations needing steroid treatment – was quite rare. Three trials recorded no exacerbations, and a third only one. Analyses ...



LAMA Plus LABA Tied to Fewer Exacerbations in Stable COPD

Wed, 04 Oct 2017 12:00:00 +0100

Also might result in greater improvement in FEV1 than LABA plus corticosteroids (Source: Pulmonary Medicine News - Doctors Lounge)



Hip pain in young athletes: Q & A with a sports medicine specialist

Tue, 03 Oct 2017 14:54:45 +0100

When your child plays a sport, it’s often hard to tell where everyday aches and pains end and a potentially serious injury begins. Bumps and bruises are anything but rare in contact sports, and muscle soreness can be a common complaint for any young athlete — especially given the rigor of youth athletics these days. So how do you know when your child’s hip pain is due to an actual injury? Dr. Mininder Kocher, orthopedic surgeon and Associate Director of the Sports Medicine Division at Boston Children’s Hospital, helps answer parents’ questions about hip pain in young athletes. What are some of the more common hip injuries you see in young athletes? The hip is a complex joint, so we see many types of injuries, both outside and inside the joint. Some of the injuries outside the j...



Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps

Tue, 26 Sep 2017 23:00:00 +0100

Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older. (Source: Drug Development Technology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Meta-Analysis: Corticosteroids Improve Pain Relief in Acute Sore Throat (FREE)

Thu, 21 Sep 2017 00:00:00 +0100

By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM A single dose of corticosteroids offers pain relief in patients with acute sore throat, according to a meta-analysis in The BMJ.Researchers … (Source: Physician's First Watch current issue)



Following regulatory win, GSK & Innoviva tout data for once-daily triple-med inhaler

Wed, 20 Sep 2017 13:42:24 +0100

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) notched a win this week after the FDA approved its once-daily, triple combination therapy for the treatment of chronic obstructive pulmonary disease. Last week, an EU agency recommended the inhaler’s approval. Now, the companies are touting results from a late-stage trial of Trelegy Ellipta, which is composed of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta agonist. Get the full story at our sister site, Drug Delivery Business News. The post Following regulatory win, GSK & Innoviva tout data for once-daily triple-med inhaler appeared first on MassDevice. (Source: Mass Device)



Boston Scientific touts 3-year Alair follow-up study results

Mon, 18 Sep 2017 15:41:30 +0100

Boston Scientific (NYSE:BSX) today released 3-year follow-up cohort results from the post-FDA approved PAS2 clinical trial of its Alair system designed for bronchial thermoplasty to treat severe persistent asthma, touting reduced severe asthma attacks, hospitalizations and ER visits. Results from the trial were recently published in the European Respiratory Journal, the Marlborough, Mass.-based company said. The PAS2 trial is an open-label study which enrolled patients at 27 North American centers, with 95% of the recruited patients considered severe asthmatics. Boston Scientific said that data from the cohort corroborated earlier data from the AIR2 trial of the device and validate the results in the real-world. “The results of the PAS2 study confirm that treatment with BT has an e...



GSK ’s triple-med COPD inhaler wins recommendation for approval in EU

Fri, 15 Sep 2017 12:40:02 +0100

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults with COPD. The device uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It’s also the first once-daily single inhaler triple therapy to win a positive opinion by the Committee for Medicinal Products for Human Use, the companies reported. Get the full story at our sister site, Drug Delivery Business News. The post GSK’s triple-med COPD inhaler wins recommendation for approval in EU appeared first on MassDevice. (Source: Mass Device)



Interventions for treating tuberculous pericarditis

Thu, 14 Sep 2017 04:00:00 +0100

(Liverpool School of Tropical Medicine) Researchers from South Africa and Canada have carried out a Cochrane review update to assess the safety and effectiveness of corticosteroids for treating tuberculous pericarditis. (Source: EurekAlert! - Infectious and Emerging Diseases)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Expensive drug driving up Medicare expenditures without evidence of greater efficacy

Mon, 11 Sep 2017 04:00:00 +0100

(Oregon State University) Medicare spent more than $1 billion over a five-year period on a high-priced drug that has not been proven more effective for a collection of inflammatory conditions than much less expensive corticosteroids. (Source: EurekAlert! - Medicine and Health)



Oral Corticosteroids of No Benefit in Nonasthmatic Adults with Lower Respiratory Tract Infection (FREE)

Wed, 23 Aug 2017 00:00:00 +0100

By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH Oral corticosteroids offer no benefit to nonasthmatic adults with acute lower respiratory tract infection, according to a placebo-controlled trial in JAMA … (Source: Physician's First Watch current issue)



Oral Corticosteroids No Benefit for LRI in Non - Asthmatic Adults

Wed, 23 Aug 2017 00:00:00 +0100

No decrease in cough duration, severity for adults without asthma with lower respiratory tract symptom (Source: Pulmonary Medicine News - Doctors Lounge)



Corticosteroid injection may offer little advantage for Morton ’s neuroma patients treated with local anesthetic

Sun, 20 Aug 2017 00:01:52 +0100

According to a study published online in the journal Foot & Ankle International, corticosteroid injection plus local anesthetic may not be superior to local anesthetic alone in terms of pain and function for patients with Morton’s neuroma.  (Source: Orthogate - Latest News)



Drug safety update: Corticosteroids: rare risk of central serous chorioretinopathy

Thu, 17 Aug 2017 08:28:20 +0100

The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a drug safety update ...... (Source: Royal Pharmaceutical Society News)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Laser in the management of burn scars

Tue, 08 Aug 2017 14:14:09 +0100

Burn scars are associated with significant morbidity ranging from contractures, pruritus, and disfigurement to psychosocial impairment. Traditional therapies include silicone gel, compression garments, corticosteroid injections, massage therapy, and surgical procedures, however, newer and advanced therapies for the treatment of burn scars have been developed. Lasers, specifically ablative fractional lasers, show potential for the treatment of burn scars. (Source: Current Awareness Service for Health (CASH))



Oral Corticosteroids Tied to Serious Adverse Events in IgA Nephropathy (FREE)

Wed, 02 Aug 2017 00:00:00 +0100

By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Oral corticosteroids for patients with immunoglobulin A nephropathy are associated with increased risk for serious infections, a JAMA study finds.Some 260 … (Source: Physician's First Watch current issue)



Infection Concern Halts Kidney Disease Drug Trial

Tue, 01 Aug 2017 18:15:19 +0100

Doctors should weigh risks, benefits related to corticosteroid use, study suggests (Source: WebMD Health)



Drug for Kidney Disease Tied to Infection Risk

Tue, 01 Aug 2017 16:00:00 +0100

Doctors should weigh risks, benefits related to corticosteroid use, study suggests Source: HealthDay Related MedlinePlus Pages: Kidney Diseases (Source: MedlinePlus Health News)



Methylprednisolone for Kidney Disease Tied to Infection Risk

Tue, 01 Aug 2017 12:08:32 +0100

TUESDAY, Aug. 1, 2017 -- A drug used for some cases of kidney disease can raise the risk of serious infections, researchers say. A clinical trial was stopped early when researchers discovered that patients on the drug -- a corticosteroid called... (Source: Drugs.com - Daily MedNews)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Fear Keeps Many Eczema Patients From Using Steroid Creams Fear Keeps Many Eczema Patients From Using Steroid Creams

Fri, 28 Jul 2017 11:12:27 +0100

Many people with eczema may avoid creams and ointments that can help ease symptoms like itching and inflammation because they ’ re afraid to try topical corticosteroids, a recent study suggests.Reuters Health Information (Source: Medscape Allergy Headlines)



NICE backs biologic for treating condition that can cause blindness

Fri, 28 Jul 2017 08:01:00 +0100

A monoclonal antibody and a biodegradable corticosteroid implant have been approved for use by the NHS in England and Wales to treat an inflammatory eye condition that can lead to blindness. (Source: Nursing Times)



Fear keeps many eczema patients from using steroid creams

Wed, 26 Jul 2017 16:59:12 +0100

(Reuters Health) - Many people with eczema, a common skin disease, may avoid creams and ointments that can help ease symptoms like itching and inflammation because they ’re afraid to try topical corticosteroids, a recent study suggests. (Source: Reuters: Health)



Clearside Biomedical launches Phase II diabetic macular edema trial

Wed, 12 Jul 2017 17:30:40 +0100

Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema. The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical launches Phase II diabetic macular edema trial appeared first on MassDevice. (Source: Mass Device)



​Ocular Therapeutix faces fraud allegations as FDA rejects eye drug

Wed, 12 Jul 2017 14:43:52 +0100

Bedford eye care biotech Ocular Therapeutix saw its share price plummet on Wednesday after the FDA rejected its lead drug for the second time. To make matters worse, the company and its top executives are now facing fraud allegations in federal court. Ocular (Nasdaq: OCUL) said after markets closed on Tuesday that the FDA had denied its application for Dextenza, a tiny insert that is placed in the eye and delivers a corticosteroid to treat pain following surgical procedures. Regulators cited manufacturing… (Source: bizjournals.com Health Care:Biotechnology headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Better Vision-related QOL With Fluocinolone Acetonide Implant for Uveitis Better Vision-related QOL With Fluocinolone Acetonide Implant for Uveitis

Wed, 05 Jul 2017 20:40:31 +0100

Treatment of noninfectious uveitis with fluocinolone acetonide implants is associated with better vision-related quality of life, compared with systemic corticosteroid therapy, according to results from the MUST research group.Reuters Health Information (Source: Medscape Ophthalmology Headlines)



School's in for asthma medication adherence

Mon, 03 Jul 2017 04:00:00 +0100

(Children's National Health System) Stephen J. Teach, M.D., M.P.H., and colleagues tried to reduce missed doses of daily medications, improve asthma control and tamp down on schoolchildren's asthma attacks by outsourcing morning delivery of inhaled corticosteroids to the school nurse. (Source: EurekAlert! - Medicine and Health)



Drug cocktail may help prevent sepsis shock, death

Mon, 26 Jun 2017 16:21:35 +0100

Researchers have found that a drug cocktail of vitamin C, corticosteroids and thiamine may help prevent progressive organ failure caused by sepsis. (Source: Health News - UPI.com)



Readily available drug cocktail may help prevent sepsis shock and death

Mon, 26 Jun 2017 04:00:00 +0100

(Elsevier) Even in advanced medical settings, sepsis is still very dangerous and accounts for over 400,000 deaths annually in the US alone. While new drugs are in development, a group of researchers has determined that a combination of intravenous vitamin C, corticosteroids (a steroid), and thiamine (vitamin B) may be effective in preventing progressive organ dysfunction and reducing the number of deaths from severe sepsis and septic shock. Their findings are published in the June issue of CHEST. (Source: EurekAlert! - Medicine and Health)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Readily available drug cocktail can help prevent sepsis shock and death

Mon, 26 Jun 2017 04:00:00 +0100

(Elsevier) Even in advanced medical settings, sepsis is still very dangerous and accounts for over 400,000 deaths annually in the US alone. While new drugs are in development, a group of researchers has determined that a combination of intravenous vitamin C, corticosteroids (a steroid), and thiamine (vitamin B) may be effective in preventing progressive organ dysfunction and reducing the number of deaths from severe sepsis and septic shock. Their findings are published in the June issue of CHEST. (Source: EurekAlert! - Social and Behavioral Science)



Thinking Machines: From Magic to Normal

Thu, 22 Jun 2017 07:22:43 +0100

“Technology made large populations possible; large populations now make technology indispensable.”                – Joseph Krutch (Writer)Since the 19th century, we have undergone several stages of machine revolutions.The first stage was mechanisation. The advent of modern production methods eased and sped up manufacturing, massively increasing output and ushering in the Industrial Revolution.The late 60s brought the age of the working computer. In 1967, an IBM infomercial, ‘The Paperwork Explosion’, predicted a dystopian future where unstoppable progress had created so much paperwork that it threatened humanity’s very existence, a development that could only be reversed with IBM’s advanced business machines. “They take care of the paperwork so you don’t ha...



Boston Scientific launches Alair asthma treatment in India

Tue, 13 Jun 2017 16:01:28 +0100

Boston Scientific (NYSE:BSX) has launched its Alair bronchial thermoplasty therapy in India, according to an India Blooms report. The device won clearance in the country with indications for treating severe, persistent, drug-resistant asthma in adult patients who’s asthma is not well controlled with inhaled corticosteroids and long acting beta antagonists. Marlborough, Mass.-based Boston Scientific’s Alair bronchial thermoplasty treatment uses a bronchoscope to deliver radiofrequency energy to reduce the amount of excess smooth muscle tissue in the airways. “There are over 18 million estimated asthmatics in the country, for some of whom currently available medication has failed to provide any relief. Our bronchial thermoplasty therapy holds great promise to help address...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Anika launches late-stage supplemental Cingal study

Fri, 26 May 2017 14:42:06 +0100

Anika Therapeutics (NSDQ:ANIK) said yesterday that it enrolled the 1st patient in a supplemental Phase III efficacy and safety trial of its Cingal hyaluronic acid-corticosteroid combination viscosupplement. The Bedford, Mass.-bsaed company is evaluating Cingal as a treatment for osteoarthritis-related knee pain. Get the full story at our sister site, Drug Delivery Business News. The post Anika launches late-stage supplemental Cingal study appeared first on MassDevice. (Source: Mass Device)



New medicine shows potential to reduce oral steroid use in severe asthma patients

Thu, 25 May 2017 04:00:00 +0100

(McMaster University) The results of the trial, published this week in the New England Journal of Medicine, demonstrate that patients treated with a potential new medicine and antibody, called benralizumab, were more than four times likely to reduce their usage of oral corticosteroids than those taking a placebo. (Source: EurekAlert! - Medicine and Health)



Boston Scientific ’ s post-approval Alair study shows long-term asthma improvement

Wed, 24 May 2017 15:10:56 +0100

Patients treated with the Alair device made by Boston Scientific (NYSE:BSX) showed long-term improvement in controlling their asthma, according to a post-approval study released today at the annual meeting of the American Thoracic Society in Washington. The Alair bronchial thermoplasty treatment uses a bronchoscope to deliver radiofrequency energy to reduce the amount of excess smooth muscle tissue in the airways. Boston acquired the technology when it paid $194 million in cash for Asthmatx in 2010, shortly after that company won 510(k) clearance from the FDA for Alair. The deal also included some $250 million in potential milestones through 2019. The 284-patient PAS2 study showed that patients treated with Alair went from a 77.8% rate of severe exacerbations to 50.6% during the 1st year ...



Novartis ’ Ultibro Breezhaler tops corticosteroid for COPD in head-to-head study

Tue, 23 May 2017 14:51:47 +0100

Novartis (NYSE:NVS) said today that a new analysis of its head-to-head Flame trial showed that inhaled corticosteroids may not be necessary in some chronic obstructive pulmonary disease patients with high blood eosiophil counts. The data demonstrated that the company’s Ultibro Breezhaler provided better or similar benefits compared to Seretide, an inhaled corticosteroid, in COPD patients regardless of eosiophil count. These results contrast with previous work suggesting better outcomes with inhaled corticosteroids for patients with high eosinophil counts. Get the full story at our sister site, Drug Delivery Business News. The post Novartis’ Ultibro Breezhaler tops corticosteroid for COPD in head-to-head study appeared first on MassDevice. (Source: Mass Device)



Anika touts Phase III data for Cingal knee therapy

Mon, 22 May 2017 18:49:10 +0100

Anika Therapeutics (NSDQ:ANIK) touted data today from a Phase III trial for its Cingal hyaluronic acid-corticosteroid combination viscosupplement as a treatment for osteoarthritis-related knee pain. The data showed that treatment with Cingal yielded better immediate and short-term pain relief compared to hyaluronic acid alone and better pain and stiffness relief through 26 weeks compared to saline. The data was published in the journal Cartilage.  Get the full story at our sister site, Drug Delivery Business News. The post Anika touts Phase III data for Cingal knee therapy appeared first on MassDevice. (Source: Mass Device)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Triple-combo inhaler for COPD wins recommendation for approval in EU

Mon, 22 May 2017 17:57:13 +0100

Chiesi Group said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended that the EMA approve its extra-fine triple combination inhaler for the treatment of chronic obstructive pulmonary disease. The Trimbow device combines an inhaled corticosteroid, a long-acting beta2-agonist and a long-acting muscarinic antagonist. The healthcare group said it is the 1st time the extra-fine triple therapy has been available in a single inhaler. Get the full story at our sister site, Drug Delivery Business News. The post Triple-combo inhaler for COPD wins recommendation for approval in EU appeared first on MassDevice. (Source: Mass Device)



What Bronchodilator Options Do We Have for COPD? What Bronchodilator Options Do We Have for COPD?

Fri, 19 May 2017 19:12:55 +0100

Are fixed combinations better than monotherapy? How should you add a corticosteroid to the regimen? Dr Gross discusses a new meta-analysis designed to clarify these issues.Medscape Pulmonary Medicine (Source: Medscape Today Headlines)



Acid-Suppressing Drugs May Blunt Corticosteroid Response in Asthma Acid-Suppressing Drugs May Blunt Corticosteroid Response in Asthma

Fri, 19 May 2017 18:31:40 +0100

Acid-suppression medications are associated with changes in the airway microbiome in patients with asthma, and these changes may affect corticosteroid response, new research suggests.Reuters Health Information (Source: Medscape Allergy Headlines)



Mepolizumab helps patients with refractory Churg-Strauss syndrome

Wed, 17 May 2017 21:44:44 +0100

Mepolizumab, an anti-IL5 monoclonal antibody, increased remission rates, cut exacerbations in half and reduced the need for ongoing corticosteroid therapy in patients with refractory cases of the rare autoimmune disease Churg-Strauss Syndrome, according to research. (Source: ScienceDaily Headlines)



Intra-Articular Corticosteroids Show No Benefit in Knee Osteoarthritis (FREE)

Wed, 17 May 2017 00:00:00 +0100

By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Intra-articular triamcinolone does not help relieve knee pain in adults with osteoarthritis — and might even lead … (Source: Physician's First Watch current issue)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Medical News Today: Knee osteoarthritis: Steroid injections offer no benefit, study suggests

Tue, 16 May 2017 16:00:00 +0100

Corticosteroid injections do not ease pain for patients with knee osteoarthritis and may even lead to greater loss of cartilage, new research suggests. (Source: Health News from Medical News Today)



Steroid Shots Do Little for Knee Pain of Arthritis

Tue, 16 May 2017 15:00:01 +0100

Corticosteroid injections were no more effective than a placebo in relieving pain or stiffness or improving the ability to walk. (Source: NYT Health)



Topical Corticosteroids

Fri, 12 May 2017 07:00:00 +0100

Title: Topical CorticosteroidsCategory: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 5/12/2017 12:00:00 AM (Source: MedicineNet Skin General)



Systemic Therapy for Uveitis Provides Better Long-term Visual Acuity Systemic Therapy for Uveitis Provides Better Long-term Visual Acuity

Wed, 10 May 2017 20:39:50 +0100

Systemic corticosteroids supplemented by immunosuppression provides better long-term visual acuity than intravitreous fluocinalone in patients with uveitis, according to results from the MUST trial.Reuters Health Information (Source: Medscape Allergy Headlines)



No Benefit From Corticosteroids for Acute, Simple Urticaria No Benefit From Corticosteroids for Acute, Simple Urticaria

Wed, 10 May 2017 20:39:13 +0100

Corticosteroids do not speed relief for patients presenting to the emergency department (ED) with acute urticaria, according to a new randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Sanofi CEPiA Product List

Wed, 10 May 2017 09:39:00 +0100

Sanofi CEPiA provides a wide range of products, including active pharmaceutical ingredients (API), corticosteroids and hormones, francopia, prostaglandins, and biotechnologies. (Source: Pharmaceutical Technology)



Systemic therapy beats Bausch & Lomb implant in NIH uveitis study

Mon, 08 May 2017 20:23:59 +0100

Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by an average of 1 line on an eye chart among patients with the implant, according to the study. Get the full story at our sister site, Drug Delivery Business News. The post Systemic therapy beats Bausch & Lomb implant in NIH uveitis study appeared first on MassDevice. (Source: Mass Device)



Systemic Tx Offers Better Outcomes in Severe Uveitis (CME/CE)

Sun, 07 May 2017 20:35:02 +0100

(MedPage Today) -- Better visual acuity with long-term corticosteroids (Source: MedPage Today Ophthalmology)



Systemic therapy outperforms intraocular implant for treating uveitis

Sun, 07 May 2017 16:31:31 +0100

Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better – and had fewer adverse outcomes – than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute (NEI). After seven years, visual acuity on average remained stable among participants on systemic therapy but declined by an average of si x letters (about one line on an eye chart) among participants who had the implant. NEI is part of the National Institutes of Health. (Source: News from NEI)



Short Term Use of Oral Corticosteroids and Related Harms Short Term Use of Oral Corticosteroids and Related Harms

Fri, 05 May 2017 04:07:46 +0100

This study examined characteristics of short-term oral corticosteroid prescriptions in the U.S., and their associated risk of adverse events.The BMJ (formerly known as the British Medical Journal) (Source: Medscape Allergy Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Appropriate Selection of Corticosteroids in Treating Asthma and COPD

Thu, 04 May 2017 16:33:00 +0100

You're dispatched to the scene of a residential facility for a patient with difficulty breathing. You and your partner arrive to find an elderly male on his living room couch in clear respiratory distress as indicated by tripod positioning with accessory muscle use, pursed lip breathing, and paradoxical chest wall/abdominal movements (positive Hoover sign). Initial impression of your patient reveals he has difficulty speaking due to his increased respiratory effort and explains that recently he's unable to catch his breath. He says he recently ran out of his home DuoNeb (ipratropium bromide/albuterol sulfate) treatments. Further questioning reveals he's a chronic smoker and has a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) and asthma, both of which are pharmacologic...



Your NEJM Group Today: Board Review & the Middle-Aged Doctor / Short-Term Corticosteroid Use / Kentucky Cardiology Opportunities (FREE)

Wed, 03 May 2017 00:00:00 +0100

By the Editors Check out today's selections from NEJM Group: NEJM Clinical Practice Center: Perspective: Reviewing for her board exam 20 years in, a physician … (Source: Physician's First Watch current issue)



Corticosteroid modulation and testosterone changes during alcohol intoxication affects voluntary alcohol drinking - Eriksson CJP, Etel älahti TJ, Apter SJ.

Tue, 02 May 2017 03:14:41 +0100

A number of studies have shown that stress and an activated hypothalamic-pituitary-adrenal (HPA) axis are associated with increased voluntary alcohol drinking. Recently, associations have been found between activated HPA and hypothalamic-pituitary-gonadal ... (Source: SafetyLit)



Corticosteroids Overprescribed in Young Asthmatics

Mon, 01 May 2017 15:30:24 +0100

Prescribing has gone from underuse to substantial overprescribing. The challenge is to get it just right. (Source: ConsultantLive)



PodMed: A Medical News Roundup From Johns Hopkins (with audio)

Sat, 22 Apr 2017 20:35:00 +0100

(MedPage Today) -- This week's topics include the dangers of short term corticosteroids, troponin assay for assessing MI, azithromycin and arrhythmia, and eye screening intervals for people with diabetes (Source: MedPage Today Cardiovascular)

MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.




Clearside closes patient enrollment in trial for diabetic macular edema therapy

Thu, 20 Apr 2017 18:31:03 +0100

Clearside Biomedical (NSDQ:CLSD) said today that it finished enrollment for the Phase 1/2 study of CLS-TA in patients with diabetic macular edema. The Hulk trial is designed to evaluate the safety and efficacy of a suprachoroidal injection of its suspension formulation of a corticosteroid, triamcinolone acetonide, with and without an intravitreal injection of Eylea in DME patients. The Alpharetta, Ga.-based company said it expects preliminary results from the study in the 2nd half of this year. Get the full story at our sister site, Drug Delivery Business News. The post Clearside closes patient enrollment in trial for diabetic macular edema therapy appeared first on MassDevice. (Source: Mass Device)



Teva launches AirDuo RespiClick, generic inhaled asthma therapies

Thu, 20 Apr 2017 17:48:57 +0100

Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid. AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered using Teva’s breath-activated RespiClick inhaler. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches AirDuo RespiClick, generic inhaled asthma therapies appeared first on MassDevice. (Source: Mass Device)



Inhaled steroids may increase pneumonia risk in people with asthma

Thu, 20 Apr 2017 04:00:00 +0100

(Wiley) Use of inhaled corticosteroids was linked with an increased risk of pneumonia in a study of individuals with asthma. (Source: EurekAlert! - Medicine and Health)



Steroids Alone Are Not a Quick Fix for Sore Throats Steroids Alone Are Not a Quick Fix for Sore Throats

Wed, 19 Apr 2017 21:31:39 +0100

A single oral corticosteroid dose in the absence of antibiotics did not reduce the clinical burden of sore throats in primary care patients in a large randomized controlled trial, nor did it reduce antibiotic use.Medscape Medical News (Source: Medscape Allergy Headlines)



Study examines effectiveness of steroid medication for sore throat

Tue, 18 Apr 2017 15:15:09 +0100

In patients with a sore throat that didn't require immediate antibiotics, a single capsule of the corticosteroid dexamethasone didn't increase the likelihood of complete symptom resolution after 24 hours, and although more patients taking the steroid reported feeling completely better after 48 hours, a role for steroids to treat sore throats in primary care is uncertain, according to a study. (Source: ScienceDaily Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.




Steroids May Be Risky Even in the Short Term

Tue, 18 Apr 2017 10:00:00 +0100

Taking oral corticosteroids for only a month or less may increase the risk of blood clots, infections and broken bones. (Source: NYT Health)



Short-Term Use of Oral Corticosteroids Tied to Sepsis, VTE, and Fracture (FREE)

Fri, 14 Apr 2017 00:00:00 +0100

By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Short-term use of oral corticosteroids is associated with increased risks for sepsis, venous thromboembolism (VTE), and fracture, according … (Source: Physician's First Watch current issue)



First Guidelines on Hip Osteoarthritis From AAOS First Guidelines on Hip Osteoarthritis From AAOS

Thu, 13 Apr 2017 20:18:24 +0100

The American Academy of Orthopedic Surgeons guidelines emphasized presurgical treatments to reduce pain and increase mobility, including corticosteroid injections and nonnarcotic pain medication.Medscape Medical News (Source: Medscape Radiology Headlines)